{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=6",
    "query": {
      "condition": "Dysmyelopoietic Syndromes",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1780,
    "total_pages": 178,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T12:34:08.817Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00867932",
      "title": "Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemoglobinuria, Paroxysmal"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 7,
      "start_date": "2009-10-02",
      "completion_date": "2011-05-12",
      "has_results": true,
      "last_update_posted_date": "2018-10-31",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 3,
      "location_summary": "Orange, California • Pensacola, Florida • Memphis, Tennessee",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00867932"
    },
    {
      "nct_id": "NCT00923364",
      "title": "Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MDS",
        "Immunodeficiency",
        "GATA2"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide (CTX, Cytoxan)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine(Fludara,Berlex Laboratories)",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell (HSC)",
          "type": "PROCEDURE"
        },
        {
          "name": "Equine Anti-Thymocyte Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "12 Years to 60 Years"
      },
      "enrollment_count": 19,
      "start_date": "2009-05-07",
      "completion_date": "2017-02-26",
      "has_results": true,
      "last_update_posted_date": "2020-03-12",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923364"
    },
    {
      "nct_id": "NCT02458235",
      "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphoid Leukemia",
        "Juvenile Myelomonocytic Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "donor lymphocyte infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 17,
      "start_date": "2015-06-02",
      "completion_date": "2019-03-15",
      "has_results": true,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02458235"
    },
    {
      "nct_id": "NCT00887068",
      "title": "Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia",
        "AML",
        "MDS"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 187,
      "start_date": "2009-04-21",
      "completion_date": "2018-08-20",
      "has_results": true,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00887068"
    },
    {
      "nct_id": "NCT01137825",
      "title": "Registry of Older Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Cognitive/Functional Effects",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2009-09",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 7,
      "location_summary": "Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more",
      "locations": [
        {
          "city": "Boone",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Hendersonville",
          "state": "North Carolina"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01137825"
    },
    {
      "nct_id": "NCT01463410",
      "title": "Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Promyelocytic Leukemia (APL)",
        "Refractory Anemia With Excess of Blasts (RAEB)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Skyline Diagnostics BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2011-10",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-05-29",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 2,
      "location_summary": "New York, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01463410"
    },
    {
      "nct_id": "NCT04734990",
      "title": "Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia-0",
        "Chronic Myelomonocytic Leukemia-1",
        "Chronic Myelomonocytic Leukemia-2",
        "Myelodysplastic Syndrome",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Seclidemstat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-07-07",
      "completion_date": "2027-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734990"
    },
    {
      "nct_id": "NCT03071276",
      "title": "Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate/hydrocortisone/cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "Up to 24 Years"
      },
      "enrollment_count": 37,
      "start_date": "2016-01-14",
      "completion_date": "2019-04-30",
      "has_results": true,
      "last_update_posted_date": "2020-05-22",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071276"
    },
    {
      "nct_id": "NCT05805605",
      "title": "Allo HSCT Using RIC and PTCy for Hematological Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Biphenotypic Acute Leukemia",
        "Undifferentiated Leukemia",
        "Prolymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Plasma Cell Leukemia",
        "Myelodysplastic Syndromes",
        "Leukemia, Myeloid",
        "Myelodysplastic Syndrome With Excess Blasts-1",
        "Burkitt Lymphoma",
        "Relapsed T-Cell Lymphoma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Marginal Zone Lymphoma",
        "Follicular Lymphoma",
        "Myeloproliferative Neoplasm",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Peripheral Blood Stem Cell Transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allopurinol 300 MG",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Cell Transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Sirolimus Pill",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 56,
      "start_date": "2023-05-01",
      "completion_date": "2028-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05805605"
    },
    {
      "nct_id": "NCT00467610",
      "title": "Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Panhematin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2007-05",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2014-10-24",
      "last_synced_at": "2026-10-14T12:34:08.817Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467610"
    }
  ]
}